Evaluation of JNK blockade as an early intervention treatment for type 1 diabetic nephropathy in hypertensive rats

American Journal of Nephrology

Volumn 34, Issue 4, 2011, Pages 337-346

  Lim, Andy K H ^a,b   Ma, Frank Y ^a,b   Nikolic Paterson, David J ^a,b   Ozols, Elyce ^a   Young, Morag J ^c   Bennett, Brydon L ^d   Friedman, Glenn C ^d   Tesch, Gregory H ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d CELGENE CORPORATION   (United States)

Author keywords

Albuminuria; Cell signaling; Diabetic nephropathy; Hypertension; Inflammation

Indexed keywords

CC 930; MACROPHAGE DERIVED CHEMOKINE; MESSENGER RNA; NEPHRIN; PODOCIN; STREPTOZOCIN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE EXACERBATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HYPERGLYCEMIA; HYPERTENSION; KIDNEY INJURY; MACROPHAGE; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

ALBUMINURIA; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CYCLOHEXANOLS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HYPERTENSION; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MALE; MAP KINASE KINASE 4; PROTEIN KINASE INHIBITORS; PURINES; RATS; RATS, INBRED SHR; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 80052102425     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000331058     Document Type: Article

References (24)

1. Fukuda K, Tesch GH, Nikolic-Paterson DJ: c-Jun amino terminal kinase 1 deficient mice are protected from streptozotocin-induced islet injury. Biochem Biophys Res Commun 2008;366:710-716.
2. Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa M, Kajimoto Y, Ichijo H, Yamasaki Y, Hori M: Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004;10:1128-1132. (Pubitemid 39424876)
3. Flanc RS, Ma FY, Tesch GH, Han Y, Atkins RC, Bennett BL, Friedman GC, Fan JH, Nikolic-Paterson DJ: A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis. Kidney Int 2007;72:698-708. (Pubitemid 47373789)
4. Ma FY, Flanc RS, Tesch GH, Bennett BL, Friedman GC, Nikolic-Paterson DJ: Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Lab Invest 2009;89:470-484.
5. Ma F, Flanc R, Tesch G, Han Y, Atkins R, Bennett B, Friedman G, Fan J, Nikolic-Paterson D: A pathogenic role for c-Jun aminoterminal kinase signaling in renal fibrosis and tubular cell apoptosis. J Am Soc Nephrol 2007;18:472-484. (Pubitemid 46193313)
6. Wang Y, Ji HX, Xing SH, Pei DS, Guan QH: SP600125, a selective JNK inhibitor, protects ischemic renal injury via suppressing the extrinsic pathways of apoptosis. Life Sci 2007;80:2067-2075. (Pubitemid 46678068)
7. Francescato HD, Costa RS, Junior FB, Coimbra TM: Effect of JNK inhibition on cisplatin- induced renal damage. Nephrol Dial Transplant 2007;22:2138-2148. (Pubitemid 47244690)
8. Kanellis J, Ma FY, Kandane-Rathnayake R, Dowling JP, Polkinghorne KR, Bennett BL, Friedman GC, Nikolic-Paterson DJ: JNK signalling in human and experimental renal ischaemia/reperfusion injury. Nephrol Dial Transplant 2010;25:2898-2908.
9. De Borst MH, Prakash J, Melenhorst WB, van den Heuvel MC, Kok RJ, Navis G, van Goor H: Glomerular and tubular induction of the transcription factor c-Jun in human renal disease. J Pathol 2007;213:219-228. (Pubitemid 47612244)
10. Huang P, Zhang Y, Jiang T, Zeng W, Zhang N: Role of aldose reductase in the high glucose induced expression of fibronectin in human mesangial cells. Mol Biol Rep 2010;37:3017-3021.
11. Guha M, Bai W, Nadler JL, Natarajan R: Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 2000;275:17728-17739. (Pubitemid 30430822)
12. Wen Y, Scott S, Liu Y, Gonzales N, Nadler JL: Evidence that angiotensin II and lipoxygenase products activate c-Jun NH2-terminal kinase. Circ Res 1997;81:651-655. (Pubitemid 27467198)
13. Deguchi J, Makuuchi M, Nakaoka T, Collins T, Takuwa Y: Angiotensin II stimulates platelet-derived growth factor-B chain expression in newborn rat vascular smooth muscle cells and neointimal cells through Ras, extracellular signal-regulated protein kinase, and c-Jun N-terminal protein kinase mechanisms. Circ Res 1999;85:565-574. (Pubitemid 29467845)
14. Lemarie CA, Simeone SM, Nikonova A, Ebrahimian T, Deschenes ME, Coffman TM, Paradis P, Schiffrin EL: Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 2009;105:852-859.
15. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N: Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol 2004;286:F278-F287. (Pubitemid 38141671)
16. Zhang A, Ding G, Huang S, Wu Y, Pan X, Guan X, Chen R, Yang T: c-Jun NH2-terminal kinase mediation of angiotensin II-induced proliferation of human mesangial cells. Am J Physiol Renal Physiol 2005;288:F1118-F1124. (Pubitemid 40677081)
17. Liu G, Zhao H, Liu B, Xin Z, Liu M, Serby MD, Lubbers NL, Widomski DL, Polakowski JS, Beno DW, Trevillyan JM, Sham HL: Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: implication for targeting protein kinases in metabolic diseases. Bioorg Med Chem Lett 2007;17:495-500. (Pubitemid 46073734)
18. Biswas SK, Peixoto EB, Souza DS, de Faria JB: Hypertension increases pro-oxidant generation and decreases antioxidant defense in the kidney in early diabetes. Am J Nephrol 2008;28:133-142. (Pubitemid 350126504)
19. Wang X, Desai K, Clausen JT, Wu L: Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 2004;66:2315-2321. (Pubitemid 41115295)
20. Lim AK, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, Tesch GH: Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 2009;52:1669-1679.
21. de Borst MH, Prakash J, Sandovici M, Klok PA, Hamming I, Kok RJ, Navis G, van Goor H: c-Jun NH2-terminal kinase is crucially involved in renal tubulo-interstitial inflammation. J Pharmacol Exp Ther 2009;331:896-905.
22. Himes SR, Sester DP, Ravasi T, Cronau SL, Sasmono T, Hume DA: The JNK are important for development and survival of macrophages. J Immunol 2006;176:2219-2228. (Pubitemid 43201669)
23. Ijaz A, Tejada T, Catanuto P, Xia X, Elliot SJ, Lenz O, Jauregui A, Saenz MO, Molano RD, Pileggi A, Ricordi C, Fornoni A: Inhibition of c-Jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. Kidney Int 2009;75:381-388.
24. Tesch GH: Macrophages and diabetic nephropathy. Semin Nephrol 2010;30:290-301.